866-851-4866
Login
Forgot?

Forget your password?
Remembered Password?
  • Home
  • Services
    • Admissions Support
    • 24.7 Clinical Support
    • Help Desk Support
    • Educational Solutions
    • Pathways to Success
  • Management Solutions
    • Account Management
    • Reports and Analytics
    • Compliance Support
    • Cost Management
  • The Clinician Blog
  • About Us
  • Contact Us
The premiere, hospice-centered, patient-focused PBM.
  • Home
  • Services
    • Admissions Support
    • 24.7 Clinical Support
    • Help Desk Support
    • Educational Solutions
    • Pathways to Success
  • Management Solutions
    • Account Management
    • Reports and Analytics
    • Compliance Support
    • Cost Management
  • The Clinician Blog
  • About Us
  • Contact Us

FDA

Home » FDA
0
0
By Jennifer Chen
In CDC, FDA
Posted July 14, 2016

Multistate Outbreak of Infections Linked to the Use of Oral Liquid Docusate

Last month, the CDC and FDA investigated a multi-state outbreak of infections caused by Burkholderia cepacia complex. B. cepacia complex is normally not a pathogen in the ambulatory setting, but [...]

READ MORE
0
0
By Jenny Chau
In FDA
Posted July 1, 2016

FDA Approves a Brand Name Change for Antidepressant Brintellix to Trintellix

Brintellix (vortioxetine) is a relatively new serotonergic antidepressant, approved to treat major depressive disorder in September 2013. In recent FDA MedWatch news, there were numerous reports [...]

READ MORE
0
0
By Jennifer Chen
In FDA
Posted June 15, 2016

No Cardiovascular Benefit on Niacin, Fenofibrate Combinations with Statins

The FDA has withdrawn approvals for the use of niacin or fenofibrate in combination with statins for the treatment of high cholesterol. The FDA also withdrew approval of the indications related [...]

READ MORE
0
1
By Jennifer Chen
In Diabetes, FDA
Posted March 24, 2016

Diabetes Medications Updates

SGLT2 inhibitors Last year, the FDA released a drug safety communication, which cautioned the use of SGLT2 inhibitors, due to case reports of ketoacidosis in patients who were being treated with [...]

READ MORE
0
0
By Christine Pham
In FDA
Posted October 23, 2015

FDA Approves Praxbind (idarucizumab), the First Reversal Agent for Pradaxa (dabigatran etexilate)

The FDA granted accelerated approval of Praxbind (idarucizumab) on October 16, 2015 for use as a specific reversal agent of the anticoagulant effects of Pradaxa (dabigatran etexilate) during [...]

READ MORE
0
0
By Jennifer Chen
In Anti-Coagulant, FDA
Posted September 4, 2015

Hospice Medication Alert: FDA Approves Anti-Clotting Drug Savaysa (edoxaban)

The U.S. Food and Drug Administration (FDA) approved another anti-clotting drug Savaysa (edoxaban) in January 2015 for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). [...]

READ MORE
Recent Posts
  • Relistor Oral Tablets for Opioid-Induced Constipation
  • Hospice Medication Alert: PharmaTech Recalls All Liquid Products
  • Hospice Medication Alert: PharmaTech Recalls All Lots of Diocto Liquid
  • Multistate Outbreak of Infections Linked to the Use of Oral Liquid Docusate
  • Hospice Medication Alert: Nuplazid (pimavanserin)
Archives
  • November 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • March 2016
  • February 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • July 2015
  • June 2015
  • April 2015
  • February 2015
  • December 2014
Categories
  • Adverse Events
  • Anti-Coagulant
  • CDC
  • COPD
  • Diabetes
  • Drug Shortage
  • FDA
  • HPS Clinical Services
  • Inhalers
  • Medication Alerts
  • Prescription Drug Take-Back Day
  • Recall
  • Symptom Management
  • Uncategorised
Partner Tools

• Pharmacy Locator

• HPS MTP

• PDMI Reports

  • Hospice Pharmacy Solutions
  • 2201 N. Central Expressway Suite 250 Richardson, TX 75080
  • 866-851-4866
  • info@hospicepharmacysolutions.com
© 2019 Hospice Pharmacy Solutions. All rights reserved.
More Information

Have any questions? Ask here!